Gray-market red flags in the peptide supply chain

Compounded peptide therapy has moved from the edges of functional medicine into mainstream prescribing over the past 24 months. That shift has pulled in suppliers who look like compounding pharmacies but are not. A licensed 503A or 503B pharmacy sits inside a federal and state framework that is not optional. A "research chemical supplier" does not.

This is the first issue of The Peak Brief. It is written for licensed providers. It does not name specific peptides, specific products, or specific suppliers. Instead, it surfaces the patterns that separate a legitimate sourcing relationship from one that will end with a provider answering questions they do not want to answer.

Red flag 01: "For research use only" in the fine print

The single most reliable indicator that a supplier is operating outside the pharmacy framework is the phrase "for research use only," "not for human use," or "not for ingestion" on the product page or the shipping paperwork. This language is a liability shield. It tells you the supplier does not consider themselves legally accountable for human use. If you prescribe from a source that uses this language, you carry all of that liability.

Red flag 02: No state pharmacy license listed

A legitimate 503A or 503B compounding pharmacy will display its state pharmacy license number on its website, on its invoices, or will provide it on request. Ask. A supplier that cannot produce a state board pharmacy license is not a pharmacy, regardless of what their marketing copy says. State boards publish licensee lookup tools. Use them.

Red flag 03: No Certificate of Analysis on request

A compounding pharmacy tests every batch. USP chapters 797 and 800 require it. A provider asking for a Certificate of Analysis should receive one within a reasonable window, tied to a specific batch or lot. If the supplier treats the request as unusual, or if the document they send is generic and unlinked to the specific product you received, you are not dealing with a pharmacy.

Red flag 04: Pricing that does not survive a sanity check

Compounding preparations have real input costs: sterile active-ingredient sourcing, compounding labor, endotoxin testing, sterility testing, packaging, and cold-chain shipping. When a supplier sells at a fraction of what compliant compounders charge, one of those inputs has been skipped. Cheap is not always gray. But a fraction-of-market price is the first signal to verify each of the other four red flags.

Red flag 05: Foreign sourcing with no FDA records

Some suppliers import active pharmaceutical ingredients from foreign manufacturers that are not registered with the FDA. The FDA Drug Master File and establishment registration records are public. Ask your supplier to identify the ingredient source. If they cannot, or will not, the answer is not "we will get back to you." The answer is "we do not source compliantly."

What to do next

• Before a first order: ask which state pharmacy license the supplier holds.
• Before a first order: ask that the Certificate of Analysis for your specific batch be sent to you.
• Before a first order: verify the pharmacy's state board record.
• If any answer is evasive, stop.

This is the floor, not the ceiling. Providers who already work with a licensed 503A compounding pharmacy through our routing tool can skip these steps. The partner we route to has been vetted on each of the five above.

Next issue, in two weeks: what USP 797 batch testing cadence actually means for provider-side due diligence.